<?xml version="1.0" encoding="UTF-8"?>
<p>Liposomes are vesicles consisting of phospholipid bilayers. They can be readily manufactured with various lipid compositions in different particle sizes and charges, allowing the tailored design of formulations that are optimal for the delivery of a biomolecule of interest (
 <xref rid="B15" ref-type="bibr">15</xref>, 
 <xref rid="B16" ref-type="bibr">16</xref>). Liposomes have shown potential for the delivery of various therapeutics 
 <italic>in vivo</italic> including siRNA, miRNA, DNA, and peptides (
 <xref rid="B14" ref-type="bibr">14</xref>, 
 <xref rid="B17" ref-type="bibr">17</xref>). CAF01 is a liposome composed of a cationic quaternary ammonium salt adjuvanted with a glycolipid immunomodulator (
 <xref rid="B18" ref-type="bibr">18</xref>). Recent work with tuberculosis and malaria antigens has shown that CAF01-delivered vaccines are able to induce good cellular and antibody responses (
 <xref rid="B19" ref-type="bibr">19</xref>, 
 <xref rid="B20" ref-type="bibr">20</xref>). Safety, tolerability, and immunogenicity of CAF01 has been tested in five phase I clinical trials in combination with four different peptide antigens including a tuberculosis vaccine candidate and an HIV-1 peptide cocktail (
 <xref rid="B21" ref-type="bibr">21</xref>).
</p>
